Uchida N, Mukai S, Wada S, Mitsui N, Sueda T, Matsuura Y, Hirai S, Baudet E
1st Department of Surgery, Hiroshima University School of Medicine, Japan.
Kyobu Geka. 1995 Jul;48(7):557-9.
Despite the increasing use of alternative techniques, endomyocardial biopsy remains the primary method for diagnosing cardiac allograft rejection. Between March 1986 and May 1994, 2,894 endomyocardial biopsies performed on 183 heart transplant patients were reviewed. A total of 53 (1.8%) complications occurred. 33 (1.1%) complications were associated with the introduction, including carotid puncture (0.9%), neurological reaction (0.1%), and pneumothorax (0.1%). Complications during biopsy included arrhythmias (0.4%) and ventricular perforation (0.2%). In addition, we observed three episodes of allergic reaction to a reusable biotome, three episodes of liver biopsy, and one case of pacemaker dislodgement. All complications were without significant long-term sequelae. In contrast to the cardiomyopathy population, no severe ventricular perforations or deaths occurred. Thus although endomyocardial biopsy has some risk, it continues to be a safe and effective way of monitoring rejection.
尽管替代技术的使用日益增加，但心内膜心肌活检仍然是诊断心脏移植排斥反应的主要方法。1986年3月至1994年5月期间，对183例心脏移植患者进行的2894次心内膜心肌活检进行了回顾。共发生53例（1.8%）并发症。33例（1.1%）并发症与穿刺操作有关，包括颈动脉穿刺（0.9%）、神经反应（0.1%）和气胸（0.1%）。活检期间的并发症包括心律失常（0.4%）和心室穿孔（0.2%）。此外，我们观察到3例对可重复使用的活检刀过敏反应、3例肝活检并发症和1例起搏器移位。所有并发症均无明显的长期后遗症。与心肌病患者不同，未发生严重的心室穿孔或死亡。因此，尽管心内膜心肌活检有一定风险，但它仍然是监测排斥反应的一种安全有效的方法。
